We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




New Hepatitis C Drugs Entail Economic Burden

By HospiMedica International staff writers
Posted on 29 Mar 2015
Print article
The cost of treating people infected with the Hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous strain on the US healthcare system.

Researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) conducted a cost-effectiveness analysis using a microsimulation model of the natural history of HCV infection to fully evaluate the cost-effectiveness and budget impacts of sofosbuvir and ledipasvir, two new therapies to treat HCV recently approved by the US Food and Drug Administration (FDA). The outcomes were quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs.

The results show that using new therapies would reduce the clinical burden of the disease, and is cost-effective in the majority of patients. Yet, while the drugs lead to improved outcomes, the cost of the newly approved oral regimen can reach as much as USD 1,125 per day. As a result, the budget required to treat all eligible patients would be a staggering USD 136 billion over the next five years. Compared with the older, interferon-based drugs, the new therapies would cost an additional USD 65 billion, whereas the cost offsets would be only USD 16 billion.

According to the researchers, these figures represent 10% of the United States’ annual prescription drug spending, which is unsustainable if used to treat the more than two million people currently infected with HCV. The researchers therefore suggest that the newer, more expensive medications would be most beneficial for select groups of patients, including those with advanced disease, have the HCV genotype 1, or are younger. The study was published on March 17, 2015, in the Annals of Internal Medicine.

“While most developed countries factor in treatment cost before approving a drug, US law prohibits considering such costs. Hepatitis C presents an unusual case where we have cost effective therapeutic options that our health care system cannot afford,” said lead author Jagpreet Chhatwal, PhD. “Considering the law also prohibits Medicare from negotiating drug pricing, the new treatment cost could strain the budget of Centers for Medicare and Medicaid Services.”

“We have millions of people who need treatment for hepatitis C and payers obviously don't have the budget to cover this tremendous expense,” added Dr. Chhatwal, an assistant professor of Health Services Research at MD Anderson. “As a result, physicians have to prioritize the new drugs to the sickest of patients, and several payers have added restrictions that only those with the most advanced disease receive treatment.”

Related Links:

The University of Texas MD Anderson Cancer Center


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Examination Table
Powerline Backrest Top

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.